Aptamer Sciences Inc. Overview
CHOOLIP & SCIENCES is a micro-cap KOSDAQ company in transition. It was founded in 2011 as Aptamer Sciences, a POSTECH spin-off built around proprietary SELEX aptamer discovery. For most of its history it was a pre-revenue platform biotech: it commercialized one approved diagnostic (the AptoDetect™-Lung blood test, MFDS Class 3, 2017), and in 2024 it took its lead therapeutic, AST-201, a GPC3-targeted aptamer-drug conjugate (ApDC™), into a Phase 1 trial. KOSDAQ listing-maintenance thresholds for revenue and pre-tax losses forced a sequence of defensive measures. These included absorbing a bioanalytical CRO (ISS) in 2024, raising equity repeatedly, and handing control to Altcast in 2025. In 2026, new management bought a US premium pet-treat brand (Choolip Inc., US$11.4M) and renamed the company after it. Today the company combines an early-clinical oncology platform (AST-201 with an MSD Keytruda supply agreement; Trop2-ApDC preclinical) with CRO, oligo-synthesis and consumer pet-nutrition revenue lines. Value depends heavily on capital-markets access.
Company's own description
In its corporate materials, the company describes itself as an R&D-driven biotech commercializing aptamer technology platforms for innovative therapeutic and diagnostic products. It positions itself as able to generate high-affinity, high-specificity aptamers, optimize them, and develop new therapeutic and diagnostic modalities from them (Scientist.com / Informa Asia TIDES exhibitor profile). Its 2024 English press release describes it as a KOSDAQ-listed leader in the aptamer field with an integrated platform, branded ApDC™ (Aptamer Drug Conjugate), focused on oncology pipelines (PR Newswire, 25 March 2024). Filing-aggregator summaries of the FY2025 annual report describe a clinical-stage biopharmaceutical company whose development pipeline also includes Aptamer Radioligand Conjugates (ApRC) and Aptamer Immune Stimulator Conjugates (ApIS) (FinancialFilings.com).
When the name changed, the company said in public statements that it would keep both the drug-development and CRO businesses, and would use distribution of healthcare and lifestyle products as an additional revenue base (Dealsite, 6 July 2026).
Independent characterization
The company is best described as a hybrid micro-cap with four economically distinct activities:
-
Aptamer therapeutics (core value driver, pre-revenue). The ApDC platform links a target-specific DNA/RNA aptamer to a cytotoxic or functional payload. The lead asset, AST-201, embeds gemcitabine within the sequence of a GPC3-binding aptamer. A Trop2-targeted ApDC (AST-203a) and an ApDC immuno-oncology candidate (AST-202) follow. The monetization model is out-licensing (technology transfer) and co-development; no license deal on a therapeutic asset has been publicly announced to date.
-
Diagnostics. AptoDetect™-Lung is a blood-based multi-protein (7-marker) aptamer assay that produces a lung-cancer risk score. It is sold in Korea through non-reimbursed (self-pay) hospital channels and, from 2023, through health-screening providers. Revenue has historically been very small.
-
Services (CRO / bioanalysis / oligo synthesis / custom aptamer discovery / reagent distribution). This line came mostly from the 2024 absorption of International Scientific Standard Inc. (ISS), a bioanalytical CRO, plus oligonucleotide synthesis and custom aptamer discovery contracts (e.g., a KRW 417M aptamer-discovery contract in September 2025). It provides recurring, contract-based revenue and helped the company meet KOSDAQ's KRW 3bn revenue threshold in FY2025.
-
Consumer pet nutrition (from March 2026). Choolip Inc. is a US (California) premium pet-treat and beverage brand. It sells mainly on Amazon and its own website, with products manufactured in Korea.
Revenue model mix (latest, FY2025). Mostly services (CRO, synthesis, discovery contracts) plus small diagnostic product sales. There is no licensing income. From FY2026, consolidated revenue should be dominated by consumer product sales via Choolip. Segment proportions are not publicly disclosed.
Value-chain position. The company sits at the discovery and early-clinical stage in therapeutics, relies on CDMOs for GMP manufacturing (a 2022 CDMO agreement with China's Asymchem for AST-201 was reported by Daum/News1, July 2024), and acts as a service provider in bioanalysis. In pet nutrition it is a brand owner with contract manufacturing in Korea.
Customer types and end-markets. Global and Korean pharma/biotech (licensing targets, CRO clients, custom-aptamer clients); Korean tertiary hospitals and health-screening centers (diagnostics); US pet owners via e-commerce and retail (pet nutrition).
Strategy
Stated strategic themes (paraphrased from company statements)
-
Platform value via out-licensing. Prove the ApDC platform clinically through AST-201, then secure technology transfer or co-development. The goal has been repeated since 2021, with targets of "within the year or H1 next year" stated in July 2024 (News1). No license had been announced as of October 2026.
-
Combination positioning in HCC. Move AST-201 from monotherapy Phase 1 into a company-sponsored Phase 2 combination with pembrolizumab under the April 2026 MSD supply agreement. Management describes this as a strategic turning point.
-
Early preclinical licensing of Trop2-ApDC (AST-203a). Leverage big-pharma interest in Trop2 to seek licensing before the clinic (Asia Economy, Jun 2026).
-
Cash-cow diversification. Build revenue through CRO and oligo services (2024–2025), then consumer healthcare and lifestyle distribution (Choolip; goods, character merchandise and e-commerce added to corporate objects in July 2026). The stated aim is to fund drug development and keep the listing in compliance.
-
Listing compliance. Keep the pre-tax-loss ratio below 50% of equity and revenue at KRW 3bn or more.
Initiatives in the last 24 months
| Initiative | Date | Detail |
|---|---|---|
| ISS merger | Jun–Aug 2024 | Revenue base plus in-house bioanalysis for ApDC programs |
| Rights offering | Aug–Nov 2024 | ≈KRW 20bn; to improve the financial structure and fund AST-201 |
| Kolon Pharma pancreatic cancer co-development | Oct 2024 | Joint development and global licensing |
| Altcast control transfer and funding package | Sep–Oct 2025 | ≈KRW 30bn total including the CB; uses stated as working capital and acquisition of other companies' securities |
| Wellnew & Co. placement | Jan–Mar 2026 | KRW 12bn; earmarked for distribution-business investment (KRW 5bn in 2026, KRW 7bn in 2027) |
| Choolip acquisition | Mar 2026 | Entry into US pet healthcare |
| MSD CTCSA | Apr 2026 | AST-201 + Keytruda Phase 2 in HCC |
| KRW 8bn placement | Apr 2026 | Working capital (details not disclosed) |
| Trop2-ApDC national grant | Jun 2026 | 2-year lead optimization and non-clinical work |
| Share consolidation 2:1 | Jun–2026 (trading halt from a "22nd" date) | Par KRW 500 → 1,000 |
| Name change and new corporate objects | Jul 2026 | Goods/souvenirs, character products, e-commerce |
| AST-201 US patent | Aug 2026 | Global IP for licensing |
ESG commitments and cost programs: none disclosed. Medium-term financial targets / guidance: none published. Historical IPO-era projections were not met (Dealsite, Aug 2022).
Products & Services
Therapeutics pipeline
| Asset | Modality / target | Payload / mechanism | Indications | Stage (latest) | Key facts |
|---|---|---|---|---|---|
| AST-201 (also BiFAp-GPC3) | ApDC; Glypican-3 (GPC3) | Gemcitabine incorporated into the aptamer DNA sequence | GPC3+ advanced solid tumors; HCC and NSCLC | Phase 1a/1b (Korea), NCT06687941 | IND filed 12 Mar 2024, approved Oct 2024. Sites: Bundang CHA, Samsung Medical Center, Severance, National Cancer Center; lead investigator Prof. Hong-jae Chon (Bundang CHA). Dosing IV on days 1, 8 and 15 of 28-day cycles. Phase 1a sets MTD/RP2D; Phase 1b expands in GPC3+ tumor types. |
| AST-201 + pembrolizumab | Combination | Anti-PD-1 synergy | Hepatocellular carcinoma | Phase 2 planned (company-sponsored); MSD supplies Keytruda under a CTCSA signed 15 Apr 2026 | MSD provides drug supply and scientific collaboration (Kukinews; Asia Economy) |
| AST-203a (Trop2-ApDC) | ApDC; Trop2 | — | Solid tumors | Lead optimization / non-clinical; national grant (2 years) from Jun 2026 | Company aims for early licensing at the preclinical stage (Asia Economy, 18 Jun 2026) |
| AST-202 | ApDC immuno-oncology; binds cancer cells and regulatory T cells (CD25 listed as a target keyword by THE VC) | — | Solid tumors (IO) | Preclinical; AACR and SITC 2023 data | Medigate News, May 2024 |
| Pancreatic cancer program | — | — | Pancreatic cancer | Co-development with Kolon Pharmaceutical (Oct 2024) | Detailed terms not publicly disclosed |
| ApRC platform | Aptamer-radioligand conjugate | Radionuclide | Hemato-oncology / others | Discovery | FinancialFilings summary of FY2025 annual report |
| ApIS platform | Aptamer-immune stimulator conjugate | Immune agonist | Oncology | Discovery | Same |
| BBB shuttle aptamer | BiFAp-based transcytosis shuttle | Carries antibodies, peptides, siRNA across the blood-brain barrier | CNS diseases | Preclinical; MTAs with several large pharma reported | BioSpectator (2020); Medigate (2021, 2024) |
| AlloMAp insulin receptor agonist/sensitizer | Allosteric modulator aptamer | Insulin receptor | Diabetes | Preclinical (historical; current status not disclosed) | CDAs with 6 global pharma reported at IPO (BioSpectator, Aug 2020) |
| Chimeric aptamer / aptamer-siRNA | Bifunctional aptamer-siRNA | siRNA delivery | Oncology | Co-development pact with Curigin (company history lists "June"; year not confirmed) | Saramin company history |
| COVID-19 neutralizing aptamer | Neutralizing aptamer | Spike binding | COVID-19 | Non-clinical grant (2021); current status not disclosed | Dealsite, Jul 2021 |
Preclinical claims for AST-201 (company-reported). Better efficacy than sorafenib in animal models, and synergy with anti-PD-1 therapy (Patsnap Synapse, citing the company's March 2024 release). The company states that the human-equivalent gemcitabine dose in AST-201 is about 30–40 mg/m², compared with 1,000 mg/m² for free gemcitabine (Daum/News1, July 2024). Management estimates that over 70% of HCC patients are GPC3-positive and that about 40% of all HCC patients form the target population. The planned path is entry as a second-line therapy with a partner, then expansion into first-line-resistant GPC3+ patients (eToday, Oct 2024). Composition patents: Korea, China and Japan (pre-2024), and the United States (registered August 2026).
Diagnostics
| Product | Description | Regulatory | Target customer | Pricing | Notes |
|---|---|---|---|---|---|
| AptoDetect™-Lung | Blood test measuring 7 serum proteins with aptamers; an algorithm generates a lung-cancer risk score; positioned as a complement to LDCT | MFDS Class 3, Sep 2017 | Tertiary hospitals (Asan Medical Center and Kyung Hee University Hospital named as customers); health-screening centers (from 2023) | Non-reimbursed (self-pay); price not disclosed | Capacity ≈300,000 tests/year (2023). China sales targeted from 2021 at IPO, but not evidenced. A US LDT route via a domestic partner with a CLIA lab was reported as under preparation in 2024. An India entry was reported in an undated 2026 headline. |
| Pancreatic and liver cancer diagnostic kits | Pipeline at IPO (approval was targeted for 2022) | Not approved per sources reviewed | — | — | Status not disclosed |
| COVID-19 aptamer antigen test | Pipeline at IPO (2020) | — | — | — | Status not disclosed |
Services
| Service | Description | Origin | Notes |
|---|---|---|---|
| Bioanalytical CRO | Non-clinical and clinical sample bioanalysis (peptides, oligos, biologics) | ISS, founded 2008 as a JV of Battelle Memorial Institute and Yuyu Pharma; merged Aug 2024 | ISS was described as generating KRW 3–5bn of annual revenue (company statement to IB Tomato, Oct 2024); price ≤KRW 2bn |
| Oligonucleotide synthesis | Custom oligo synthesis | In-house | Part of ≈KRW 0.6bn Q1 2025 revenue |
| Custom aptamer discovery | SELEX discovery and optimization for partners | In-house platform | Example: KRW 417M contract with a domestic targeted-oncology developer, 26 Sep 2025 |
| Research reagent / sample distribution | Distribution of clinical-analysis and research reagents and samples | Expanded 2025 | Money Today, Jul 2025 |
Consumer / pet nutrition (Choolip Inc., USA)
| Product | Description | Launch | Channel | Notes |
|---|---|---|---|---|
| Squeeze Vita Stick | Creamy paste-type pet treat with 30+ vitamins and nutrients; seven organ-targeted variants (joints, kidney, heart, eyes, skin, liver, brain) | Oct 2023 (first products on Amazon and own site) | Amazon, own e-commerce; Costco referenced in media headline | Amazon's Choice within two months of launch (company claim) |
| Berry Good Milk | Lactose-free vitamin-fortified pet beverage made with Korean grade-1A raw milk | — | Same | Won first place in the cat category of the SuperZoo 2024 new product showcase |
Choolip's 2025 Amazon sales were 94,789 units, with annual order value of US$2,828,360 (Money Today, 26 Mar 2026, citing the company). All products are manufactured in Korea (HiNews, Sep 2026). There is a discrepancy: the founding date is reported as January 2024 (Montrose, California), while the first product launch is reported as October 2023. The brand may have predated incorporation of the acquired US entity.
Financial Narrative
Basis: Separate (non-consolidated) K-IFRS statements, KRW bn. DART statements were not directly accessed. Figures come from disclosure-derived media reports and aggregators. Blank cells are not publicly verified.
Income statement: notes and sources
Sources: FY2022–FY2023 net losses from IB Tomato (21 Oct 2024). FY2024 from DigitalToday (citing the FY2024 audit). FY2025 from FinancialFilings (FY2025 annual report filed 13 Mar 2026). Revenue never exceeded KRW 1bn from listing (FY2020: KRW 0.229bn) through FY2023 (IB Tomato). Dealsite (Sep 2024) described annual revenue of roughly KRW 0.2–0.3bn before the ISS merger. No dividends were found in any reviewed source; this is consistent with continuous losses.
Pre-window reference: notes and sources
Source: Kiwoom company reports (Dec 2020, Jun 2021, Oct 2021). FY2020 revenue and net loss are from IB Tomato.
Margins (computed)
Revenue CAGR over FY2021–FY2025 is not computable from verified data, and gross and EBITDA margins are not disclosed.
Balance sheet
FY2025 liabilities are derived (assets minus equity). Current ratios are from THE VC. Cash, total debt (short/long split), goodwill and intangibles, and working capital are not publicly verified. FY2020 reference (Kiwoom): current assets KRW 35.3bn, total liabilities KRW 1.7bn, BPS KRW 4,046.
Ratios (computed where possible)
ROIC, net debt/EBITDA, interest coverage and the cash conversion cycle are not meaningful (negative EBITDA) or not disclosed.
Commentary
Trend. The company has never been profitable. Net losses widened from about KRW 3.8bn (FY2020) to KRW 7.1bn (FY2022) and a peak of KRW 13.6bn (FY2023). The FY2023 peak likely reflected pre-clinical and IND-enabling spending plus possible impairments (composition not disclosed). Losses then eased to KRW 8.7bn (FY2024) and KRW 8.6bn (FY2025). Annual cash burn of about KRW 9–10bn (FY2025 operating cash outflow KRW 9.67bn) against equity in the high-20s KRW bn implies a short self-funded runway without fresh capital, and the company has in fact raised equity or CBs in every year since 2024.
Inflection 1 — KOSDAQ maintenance pressure (2023–2025). As a technology-special listing, the company lost its grace period from the pre-tax-loss test in 2023 and from the KRW 3bn minimum revenue test in 2025 (Dealsite, Jul 2026). It responded in three ways. It boosted equity through the 2024 rights offering and asset revaluation, which brought the pre-tax-loss-to-equity ratio to about 34%, below the 50% limit (Dealsite, Jul 2026). It acquired revenue by merging in ISS. And it pursued contract services. FY2025 revenue of KRW 3.50bn cleared the KRW 3bn threshold by a thin margin.
Inflection 2 — Change of control and capital injection (H2 2025). Altcast-led placements (KRW 20bn announced) and a KRW 10bn CB raised assets from KRW 32.0bn to KRW 41.1bn. Liabilities roughly doubled to about KRW 12.9bn, consistent with the CB being booked as debt. Equity rose only KRW 2.8bn despite announced placements of KRW 20bn and a KRW 8.6bn loss. Analyst inference: not all announced placement proceeds appear to have been received by 31 Dec 2025, or other equity movements offset them; reconcile with the FY2025 statement of changes in equity.
Inflection 3 — Pet-nutrition consolidation (FY2026). Choolip's reported 2025 Amazon order value of about US$2.8M (≈KRW 4bn) is larger than the parent's entire FY2025 revenue. From Q2 2026, consolidated revenue should step up materially, gross margin will reflect consumer-goods economics, and goodwill and intangibles from a KRW 17.2bn purchase price will appear on the balance sheet.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Business Lines
| Business line | Contents | Products / services | Status |
|---|---|---|---|
Drug development (ApDC and platforms) | GPC3, Trop2, Treg/CD25 programs; ApRC, ApIS, BBB shuttle, AlloMAp, BiFAp | AST-201, AST-202, AST-203a; legacy diabetes and CNS programs | Clinical (Ph1) and preclinical; no revenue |
Diagnostics | Aptamer multiplex blood tests | AptoDetect™-Lung | Approved in Korea (2017); small sales |
Services | Bioanalytical CRO (ex-ISS), oligo synthesis, custom aptamer discovery, research reagent/sample distribution | Contract services | Revenue-generating since H2 2024 |
Consumer / pet nutrition (from Mar 2026) | Choolip Inc. (USA) | Squeeze Vita Stick, Berry Good Milk | Revenue-generating; consolidation from Q2 2026 |
Goods / character / e-commerce (planned) | Added to corporate objects July 2026 | Not yet disclosed | Planned |
Business Lines (Annual)
| Business line (KRW Bn) | FY2024 | FY2025 |
|---|---|---|
Total revenue (KRW Bn) | 1.08 | 3.50 |
Drug development / licensing (KRW Bn) | 0 | 0 |
Income Statement
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW Bn) | — | — | — | 1.08 | 3.50 |
Operating income (KRW Bn) | — | — | — | -7.10 | — |
Net income (KRW Bn) | — | -7.10 | -13.60 | -8.70 | -8.62 |
Dividends per share (KRW) | 0 | 0 | 0 | 0 | 0 |
Income Statement and Per-Share Data
| Metric | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 |
|---|---|---|---|---|---|
Revenue (KRW Bn) | 0.1 | 0.2 | 0.3 | 0.4 | 0.23 |
Operating income (KRW Bn) | -1.4 | -1.9 | -3.4 | -3.3 | — |
Net income (KRW Bn) | -1.4 | -1.9 | -7.3 | -3.9 | -3.8 |
EPS (KRW) | -598 | -647 | -2,252 | -631 | — |
Margin Analysis (%)
| Metric | FY2024 | FY2025 |
|---|---|---|
Operating margin (%) | -657.4 | — |
Net margin (%) | -805.6 | -246.3 |
Revenue growth YoY (%) | — | 224.1 |
Balance Sheet and Margin Analysis (%)
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Total assets (KRW Bn) | — | 32.0 | 41.11 |
Total liabilities (KRW Bn) | — | 6.5 | 12.88 |
Total equity (KRW Bn) | — | 25.4 | 28.23 |
Paid-in capital (KRW Bn) | — | — | 20.58 |
Current ratio (%) | 164.3 | 483.6 | 224.4 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansCash Flow
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow (KRW Bn) | — | — | — | — | -9.67 |
Dividends paid (KRW Bn) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2024 | FY2025 |
|---|---|---|
ROE on year-end equity (%) | -34.3 | -30.5 |
ROA on year-end assets (%) | -27.2 | -21.0 |
Total liabilities to equity (x) | 0.26 | 0.46 |
Asset turnover (x) | 0.03 | 0.09 |
Share Price History
| Date | Price / data point | Source |
|---|---|---|
52 weeks to Dec 2020 | High KRW 32,750 / low KRW 19,800 | Kiwoom |
1 Dec 2020 | KRW 24,600; market cap KRW 208.3bn | Kiwoom |
30 Jun 2021 | KRW 21,550; market cap KRW 182.4bn | Kiwoom |
21 Oct 2021 | KRW 19,700; market cap KRW 166.8bn | Kiwoom |
Sep 2023 | ≈KRW 955 (shown in the Money Today ticker; quote time unclear) | Money Today |
26 Sep 2025 | KRW 1,010 | DigitalToday |
27 Oct 2025 | KRW 1,067 | DigitalToday |
Jan 2026 | Reference price KRW 1,107 (placement pricing) | Dealsite |
26 Mar 2026 | ≈KRW 690–721 (tickers at different times) | Money Today |
16 Jul 2026 | KRW 941 (close) | Asia Economy ticker |
Share Count (millions)
| Metric | FY2021 | FY2025 |
|---|---|---|
Shares outstanding (millions) | 8.466 | 40.257 |
Valuation Multiples
| Multiple | CHOOLIP & SCIENCES | Note |
|---|---|---|
EV/Sales (FY2025) | ≈17x (computed: ≈KRW 60.7bn market cap ÷ KRW 3.50bn revenue, ignoring net cash or debt) | — |
P/B (FY2025) | ≈2.2x (computed: KRW 60.7bn ÷ KRW 28.23bn equity) | Gurufocus showed 4.95x at an earlier, unspecified date |
Analyst Conclusions
Management guidance
No quantitative financial guidance has been published. Qualitative priorities:
-
Advance AST-201 monotherapy Phase 1 and start the MSD-supported Keytruda combination Phase 2 in HCC.
-
Optimize the Trop2-ApDC lead and seek preclinical licensing.
-
Pursue global licensing and co-development of AST-201 using the US patent.
-
Maintain the CRO business and expand healthcare and lifestyle distribution through Choolip to stabilize cash flow.
Consensus expectations
There is no sell-side consensus.
Bull case
-
Clinical validation plus licensing. The MSD supply agreement and the US patent make AST-201 a more credible licensing asset. A positive signal from Phase 1 or the early combination study in GPC3+ HCC could trigger a China-focused license, which is the company's stated priority market.
-
Revenue step-change. Choolip's 2025 Amazon order value (about US$2.83M) already exceeds parent revenue. Consolidation could lift FY2026 revenue several-fold and sharply reduce listing-maintenance risk.
-
Capitalized ownership. Two strategic holders (the Altcast group and Wellnew & Co.) have injected about KRW 40bn since Sept 2025, with one-year lock-ups. That signals continued sponsor support for funding.
Bear case
-
Platform without proof. After more than 10 years and multiple deal-timing promises, no therapeutic license exists. ApDC human efficacy is unproven, and the HCC standard of care is strong.
-
Dilution machine. Equity has been raised every year, and a KRW 10bn CB overhang remains.
-
Identity drift. Renaming the company after a pet-treat brand, adding goods and character-merchandise objects, and a shrinking R&D headcount point to declining capital and attention for drug development.
Catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Expected timing | Why it matters |
|---|---|---|
| AST-201 Phase 1 safety/efficacy data (MTD/RP2D) | Next congress cycle (not dated) | Gate for Phase 2 and licensing |
| First patient dosed in the AST-201 + Keytruda Phase 2 | 2026–2027 | Execution of the MSD collaboration |
| Q3 2026 quarterly report (consolidated) | Mid-Nov 2026 | First clear view of Choolip revenue, margins and goodwill |
| FY2026 annual report | Mar 2027 | Listing-test compliance; impairment testing |
| Any AST-201 or Trop2 licensing announcement | Unspecified | Core value-realization event |
| CB conversions and new placements | Ongoing | Dilution |
| Clarification or disclosure of the AriBio and India headlines | Ongoing | Separates rumor from fact |
| KRX surveillance status (investment warning, possible trading halt) | Near term | Trading risk |
| Executive and R&D headcount trends | Ongoing | Capacity to execute the pipeline |
Concluding analyst verdict
CHOOLIP & SCIENCES is no longer the pure-play aptamer biotech that listed on KOSDAQ in 2020 as Aptamer Sciences. The scientific core is real. The company has proprietary SELEX discovery, an approved aptamer diagnostic, and a first-in-class GPC3-targeted ApDC (AST-201) now in a multi-center Korean Phase 1. That asset has composition IP across the four most important jurisdictions and a Keytruda supply agreement with MSD for a combination study in liver cancer. These are credible assets for a company of this size, and the Trop2-ApDC grant adds a second licensing option in a target class big pharma values.
The financial record, however, dominates the investment case. Revenue stayed below KRW 1bn for most of its listed life. Losses have run at KRW 7–14bn a year. Every year since 2024 has required new equity or convertible debt simply to fund operations and keep the listing compliant. The 2025 sale of control to Altcast, the 2026 placements, the Choolip acquisition and the rename show that the new sponsors are optimizing for listing durability and near-term revenue rather than a focused drug-development strategy.
The investment case is therefore binary and event-driven. A clinical readout or licensing deal for AST-201 or the Trop2 program could revalue the platform well above the current market capitalization. Without one, the company's value rests on a small consumer pet-nutrition business and a CRO, with continuing dilution. Investors and corporate counterparties should focus on three things: AST-201 Phase 1 data and Phase 2 initiation, the first consolidated quarters showing Choolip's real contribution and margins, and the cadence of further equity issuance. Absent licensing evidence, we regard the stock as a high-risk, speculative micro-cap whose biotech optionality is real but under-resourced.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Background | Source |
|---|---|---|---|---|
Jib-hoon Jung (정집훈) | CEO and inside director | CEO from 27 Oct 2025 | Born 10 Jul 1972. Concurrently CEO of Altcast (KOSDAQ) since 21 Jan 2025 and CEO of Benoti&R (베노티앤알) since 29 Mar 2019, which the filing lists as KOSDAQ-listed. Held no shares personally at appointment. | DigitalToday (CEO change disclosure) |
Dong-il Han (한동일) | Co-founder; CEO 2011 – Oct 2025 | ≈14 years | Led POSCO's aptamer business planning from 2005; sold his controlling stake to Altcast in Sept 2025 | BioSpectator; Dealsite |
Young-ki Yoon (윤영기) | Executive Director (전무) | Named as filing officer in the FY2021 report | — | FY2021 annual report |
Kwang-yong Lee (이광용) | Executive Director / CBO | Cited 2024 | — | Medigate News, May 2024 |
Jung-eun Choi (최정은) | Executive Director, clinical development | Joined ≈2023 | Pharmacy BS/MS/PhD, Ewha Womans University; prior clinical development roles at Boryung, JW Pharmaceutical, Kainos Medicine | BioSpectator |
Dae-kyun Lee (이대견) | Head of Drug Discovery Research Institute | Cited 2022 | — | Newsis, Feb 2022 |
Ki-seok Kim (김기석) | Head of Research Institute (earlier era) | — | — | BioSpectator |
Major Shareholders
| Holder | Shares / stake | Date | Source |
|---|---|---|---|
Altcast Inc. and related parties (incl. Daehyun Gigun; Lamicus, the largest shareholder of Altcast's largest shareholder) | 13,665,891 shares (33.95%) | End Q3 2025 | Dealsite, Jan 2026 |
Altcast group (pro forma after Wellnew placement) | ≈26.1% | Mar 2026 | Dealsite, Jan 2026 |
Wellnew & Co. (웰뉴앤코) | 12,000,000 shares (22.9% post-issue) | Mar 2026 | Dealsite, Jan 2026 |
Sunbox, Hoonis | KRW 2.5bn each of the Sept 2025 placements | Oct–Nov 2025 | Dealsite, Sep 2025 |
KP Investment; OU Investment | CB holders (KRW 7bn and KRW 3bn; conversion price KRW 1,230 before consolidation) | Sep 2025 | Dealsite |
April 2026 placement investor(s) | KRW 8bn (identity not disclosed in sources reviewed) | Apr 2026 | JobKorea |
Former founder group (Han + 5 related parties) | 32.7% | 2020–2021 | Kiwoom |
Competitive Landscape
Competitors by Segment
| Business line | Competitor | Type | Relevance |
|---|---|---|---|
Aptamer platforms | Aptamer Group plc (UK, AIM) | Aptamer discovery services and diagnostics | Direct platform/services peer |
Aptamer platforms | SomaLogic (part of Standard BioTools, USA) | Aptamer (SOMAmer) proteomics | Platform heritage; proteomics diagnostics |
Aptamer platforms | Base Pair Biotechnologies (USA) | Custom aptamer development | Services peer |
Aptamer therapeutics | Astellas (Izervay, via Iveric Bio) | Approved aptamer drug (2023) | Validates the modality; different therapeutic area |
ADC / Trop2 | Gilead Sciences (Trodelvy) | Approved Trop2 ADC | Benchmark for AST-203a |
ADC / Trop2 | AstraZeneca / Daiichi Sankyo (Datroway, Trop2 ADC) | Approved Trop2 ADC | Benchmark for AST-203a |
ADC platforms (Korea) | LigaChem Biosciences (KOSDAQ) | ADC linker/payload platform with global licenses | Competes for licensing attention |
HCC therapy | Roche (atezolizumab + bevacizumab); AstraZeneca (durvalumab + tremelimumab) | Standard-of-care first-line HCC | Defines the bar for AST-201 combinations |
GPC3-targeted therapy | CARsgen (GPC3 CAR-T); Chugai/Roche (historical GPC3 antibody) | GPC3 programs | Target-level competitors |
Lung cancer blood tests | Protan Bio; Genecurix; Xenohelix (Korea); Biodesix (USA, Nodify); DELFI Diagnostics (USA) | Proteomic/fragmentomic tests | Direct diagnostic competitors (THE VC peer set for Korea) |
Bioanalytical CRO (Korea) | Bio Toxtech; Dt&CRO; other domestic bioanalysis labs | Non-clinical CRO | Services competitors |
Pet treats / supplements (USA) | Inaba (CIAO Churu lickable puree); Mars (Temptations, Greenies); Nestlé Purina; Zesty Paws (H&H Group) | Pet treats and supplements | Direct category competitors for Squeeze Vita Stick |
Competitor Detail
| Metric | CHOOLIP & SCIENCES |
|---|---|
Revenue | KRW 3.50bn (FY2025) |
Growth | +224% FY2025 (computed) |
Net margin | −246% (FY2025, computed) |
Lead asset stage | Phase 1 (AST-201) |



